/MYNZ
MYNZ Stock - Mainz Biomed B.V.
Healthcare|Medical - Diagnostics & ResearchNASDAQ
$1.20-2.44%
$0.03 (-2.44%) • Dec 19
56
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.5
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).70
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+10.0%upside
Target: $1.32
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MYNZ
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$1.19 – $1.21
TARGET (TP)$1.38
STOP LOSS$1.10
RISK/REWARD1:1.8
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.28
52W High$8.20
52W Low$0.92
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $893,991 | $895,479 | $529,877 | $577,348 | $493,565 |
| Gross Profit | $574,883 | $509,659 | $182,151 | $177,622 | $123,085 |
| Gross Margin | 64.3% | 56.9% | 34.4% | 30.8% | 24.9% |
| Operating Income | $-18,695,408 | $-26,644,682 | $-26,444,040 | $-9,724,606 | $-766,090 |
| Net Income | $-21,650,663 | $-26,295,727 | $-26,452,725 | $-11,690,098 | $-586,895 |
| Net Margin | -2421.8% | -2936.5% | -4992.2% | -2024.8% | -118.9% |
| EPS | $-22.36 | $-1.62 | $-1.87 | $-1.67 | $-0.05 |
Company Overview
Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
2
50%
Hold / Neutral
2
50%
Sell / Underperform
0%
Analyst Consensus🟡 Mixed
2 Bullish2 Neutral/Bearish
Price Targets
$20
Average Target
↑ 1525.0% Upside
Now
$14
Low
$20
Average
$25
High
Based on 2 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| February 14th 2025 | Maxim Group | Initiation | Buy | $14 |
| November 25th 2024 | H.C. Wainwright | Downgrade | Neutral | - |
| November 21st 2023 | Cantor Fitzgerald | Downgrade | Neutral | - |
| June 21st 2022 | H.C. Wainwright | Initiation | Buy | $25 |
Earnings History & Surprises
MYNZBeat Rate
33%
Last 6 quarters
Avg Surprise
-570.1%
EPS vs Estimate
Beats / Misses
2/4
Last 12 quarters
Latest EPS
$-2.65
Q3 2025
EPS Surprise History
Q2 22
No data
Q4 22
-125.9%
$-0.97vs$-0.43
Q2 23
+4.3%
$-18.00vs$-18.80
Q4 23
+22.0%
$-15.60vs$-20.00
Q2 24
-2900.0%
$-9.60vs$-0.32
Q4 24
-254.5%
$-15.60vs$-4.40
Q2 25
-166.7%
$-9.60vs$-3.60
Q3 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 26, 2025 | — | $-2.65 | — | — |
Q2 2025 | Apr 8, 2025 | $-3.60 | $-9.60 | -166.7% | ✗ MISS |
Q4 2024 | Dec 26, 2024 | $-4.40 | $-15.60 | -254.5% | ✗ MISS |
Q2 2024 | Apr 9, 2024 | $-0.32 | $-9.60 | -2900.0% | ✗ MISS |
Q4 2023 | Nov 16, 2023 | $-20.00 | $-15.60 | +22.0% | ✓ BEAT |
Q2 2023 | May 16, 2023 | $-18.80 | $-18.00 | +4.3% | ✓ BEAT |
Q4 2022 | Nov 2, 2022 | $-0.43 | $-0.97 | -125.9% | ✗ MISS |
Q2 2022 | May 2, 2022 | — | $-1.30 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.02 | — | — |
Q4 2020 | Dec 31, 2020 | — | $-0.01 | — | — |
Q2 2020 | Jun 30, 2020 | — | $-0.01 | — | — |
Q4 2019 | Dec 31, 2019 | — | $-0.02 | — | — |
Q2 2019 | Jun 30, 2019 | — | $-0.02 | — | — |
Latest News
Mainz Biomed Signs MOU With OncoVanguard8 To Introduce ColoAlert To South America
📈 PositiveBenzinga•Nov 18, 2025, 01:09 PM
Mainz Biomed Announces Topline Results From Feasibility Study, Examining Non-Invasive Blood-Based Screening Test For Early Detection Of Pancreatic Cancer, Initiated Earlier In 2025
📈 PositiveBenzinga•Oct 8, 2025, 01:05 PM
Mainz Biomed Launches ColoAlert Colorectal Cancer Test In Switzerland
📈 PositiveBenzinga•Sep 23, 2025, 12:08 PM
Mainz Biomed's ColoAlert Receives MHRA Approval For Colorectal Cancer Screening In The UK
📈 PositiveBenzinga•Sep 2, 2025, 12:11 PM
Mainz Biomed launches public offering of units and warrants
➖ NeutralSeeking Alpha•May 14, 2025, 05:33 PM
Frequently Asked Questions about MYNZ
What is MYNZ's current stock price?
Mainz Biomed B.V. (MYNZ) is currently trading at $1.20 per share. The stock has moved -2.44% today.
What is the analyst price target for MYNZ?
No analyst price targets are currently available for this stock.
What sector is Mainz Biomed B.V. in?
Mainz Biomed B.V. operates in the Healthcare sector, specifically within the Medical - Diagnostics & Research industry. The company is traded on the NASDAQ exchange.
What is MYNZ's market cap?
Mainz Biomed B.V. has a market capitalization of $0.00 billion, making it a small-cap company.
Does MYNZ pay dividends?
No, Mainz Biomed B.V. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorBNBX
BNB Plus Corp.
$2.51
Mkt Cap: $0.0B
BNGO
Bionano Genomics, Inc.
$1.60
Mkt Cap: $0.0B
CHEK
Check-Cap Ltd.
$1.61
Mkt Cap: $0.0B
FLGC
Flora Growth Corp.
$7.31
Mkt Cap: $0.0B
GBS
GBS Inc.
$0.47
Mkt Cap: $0.0B
HSCS
HeartSciences Inc.
$2.36
Mkt Cap: $0.0B
IBO
Impact BioMedical Inc.
$0.65
Mkt Cap: $0.0B
KTTA
Pasithea Therapeutics Corp.
$1.16
Mkt Cap: $0.0B
POAI
Predictive Oncology Inc.
$5.95
Mkt Cap: $0.0B
VYNE
VYNE Therapeutics Inc.
$0.59
Mkt Cap: $0.0B
Explore stocks similar to MYNZ for comparison